Anacor Pharmaceuticals Inc
How Did Ziopharm Keep XBI from Losing More Ground?
Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.
Dupixent Could Substantially Drive Regeneron’s Growth
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
New Product Launches May Boost Valeant’s Dermatology Revenue
New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after 2018 through new product launches. On December 12, 2016, the company hired Bill Humpries as executive vice president and head of the dermatology team. The change […]
Pfizer Purchases Anacor in a $5.2 Billion Cash Deal
On May 16, 2016, Pfizer (PFE) announced that it was acquiring dermatology pharma company Anacor (ANAC) in a transaction valued at $5.2 billion.
Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva
Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages
Behind Valeant’s Significant Drop in Jublia Sales
In 4Q15, Jublia added $68 million to the top line of Valeant—the sixth-largest revenue contributor in 4Q15, down from the second-largest in 3Q15.
Expectations for Valeant Pharmaceuticals in 2016
Valeant Pharmaceuticals (VRX) expects 2016 revenues to be $12.5–12.7 billion, up by 21%. In January 2016, the company launched its Valeant Access Program in partnership with Walgreens.
Jublia: Valeant’s Major Drug in Its Dermatology Portfolio
Revenue from Jublia amounted to $106 million, or 3.8%, of Valeant Pharmaceuticals’ (VRX) total revenue for 3Q15. At peak sales, Valeant expects Jublia to generate $300–$800 million.
Anacor Pharmaceuticals Outperforms the Market
Within IBB, stocks like Receptos and Celgene performed well. However, Anacor Pharmaceuticals outperformed everyone with an eye-catching 71.92% for the week ending July 17.
Healthcare and Biotech Stocks Accelerate Their Longer-Term Trends
As of July 17, 2015, 68.42% of the biotech sector within the iShares Nasdaq Biotechnology (IBB) stocks are trading above their 100-day moving average.
Mergers and Acquisitions Drive the Biotech Sector
Mergers and acquisitions continue to drive the biotech sector. In the week ending July 17, 2015, Celgene (CELG) acquired Receptos (RCPT) for ~$7.2 billion.